Abstract Vascular calcification, prevalent in diabetes and chronic kidney disease, contributes to morbidity and mortality. To investigate the effect of receptor activator of NF-kB ligand (RANKL) on vascular calcification in vivo, transgenic mice, where RANKL expression was targeted to vascular smooth muscle cells using the SM22a promoter (SM22a-Rankl tg ), were created. Sixteen-month-old male SM22a-Rankl tg mice had higher body weight and higher serum calcium levels but lower lumbar bone mineral density (BMD) compared with age-and gender-matched wild-type (WT) littermates. BMD of long bones, body fat (percent of weight) of the leg, and serum levels of phosphate and RANKL were not significantly different. No significant differences in these parameters were observed in female mice. Histological analysis did not reveal calcium deposits in the aortic roots of SM22a-Rankl tg mice. To analyze the osteoblastic differentiation and mineralization potentials of vascular cells, aortic smooth muscle cells (SMCs) were isolated and cultured. Results showed that SM22a-Rankl tg SMCs had higher baseline alkaline phosphatase (ALP) activity but not baseline matrix calcification. When induced by the PKA agonist forskolin, ALP activity was greater in SM22a-Rankl tg than in WT SMCs. Real-time RT-qPCR revealed higher baseline expression of ALP and ankylosis genes but lower osteoprotegerin gene in SM22a-Rankl tg SMCs. Matrix mineralization induced by inorganic phosphate or forskolin was greater in SM22a-Rankl tg than in WT SMCs. Treatment of these cells with the ALP inhibitor levamisole abolished forskolin-induced matrix mineralization but not inorganic phosphate-induced matrix mineralization. These findings suggest that RANKL overexpression in the vasculature may promote mineralization potential.
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Vascular calcification is present in half of middle-aged individuals and in 90 % of those over age 70 [1] . It particularly affects patients with atherosclerosis, diabetes, end-stage renal disease, and other metabolic disorders [2] . It dramatically alters vascular physiology, and key molecular regulators need to be identified to develop therapeutic approaches. We previously developed an in vitro model in which aortic cells undergo osteogenic differentiation with matrix mineral formation [3] . Using both in vitro cell culture and in vivo studies, we and others have demonstrated that many of the same factors that modulate bone formation and resorption, including cytokines and hormones, also modulate vascular calcification [4] [5] [6] [7] [8] [9] .
Two cytokines, receptor activator of NF-jB ligand (RANKL) and its soluble decoy receptor osteoprotegerin (OPG), have a central role in controlling the differentiation of osteoclasts [10] . Their potential role in vascular calcification is evidenced by the unexpected finding of extensive aortic mineralization in mice deficient in OPG [11] . Since the absence of OPG results in unopposed activity of RANKL, RANKL may promote vascular calcification. In support of this, calcified arteries are known to have higher levels of RANKL expression and lower levels of OPG [12, 13] . However, other findings suggest a more complex picture. Epidemiological studies show that vascular calcification is inversely related to serum RANKL and positively related to serum OPG [14] [15] [16] [17] [18] . Moreover, some in vitro studies showed that RANKL treatment induced vascular calcification [19, 20] , whereas we and others found no effect [21, 22] , albeit in different species and culture conditions.
In previous studies with RANKL transgenic mice, the overexpression was global or the distribution systemic. Mice with ubiquitous RANKL overexpression die at the late fetal stage [23] . Mice with overexpression of soluble RANKL, released from the liver, have osteoporosis [23] . These models would not be suitable for studying the role of RANKL in vascular calcification since bone and vascular mineralization share many endocrinological mechanisms and excess resorption in bone may cause spontaneous mineral deposition in other tissues, including arteries. Thus, in the present study we targeted the expression of RANKL to vascular smooth muscle cells (SMCs) in mice (SM22a-Rankl tg ). The results showed no effect of vascular cell-specific RANKL overexpression on basal levels of calcification but enhancement of osteoblastic differentiation and matrix mineralization in vascular cells treated with inorganic phosphate (Pi) and the PKA agonist forskolin.
Methods

Generation of the Rankl tg Mouse
The promoter sequence for the SM22a gene was PCRamplified from pSM1343-luciferase vector (1,344 bp of the 5 0 promoter and 62 bp of intron 1; kindly provided by Dr. Eric Olson, University of Texas Southwestern Medical Center, Dallas, TX) into pCR-Script vector (kindly provided by Dr. Scott Simonet, Amgen). The first coding sequence (CDS1) of the full-length (membrane-bound) murine RANKL cDNA (951 bp) was then subcloned into the newly constructed SM22a promoter transgenic expression vector [24] . The sequences of the subcloned SM22a and Rankl gene were confirmed by direct and reverse-strand sequencing and compared with the published GeneBank entries (SM22a promoter U36589, RANKL AF053713). Gel-purified, linearized transgenic constructs were microinjected into the male pronucleus of fertilized C57BL/6 one-cell oocytes. Surviving oocytes were subsequently transplanted into the oviducts of pseudopregnant foster mothers. Transgenic founder mice (on a C57BL/6 background) were identified by PCR analysis of genomic DNA isolated from tail biopsies.
To minimize variability, we used a line with high penetrance for subsequent studies. The relative copy number of the transgene was determined to be approximately 14-16 (Charles River, Troy, NY). Animals were fed a normal chow diet ad lib. At necropsy, blood, heart, aorta, and long bones were isolated. The experimental protocols were reviewed and approved by the Office of Animal Research Oversight of the University of California at Los Angeles and the Institutional Animal Care and Use Committee at Amgen.
Bone Mineral Density
Bone mineral density (BMD) was determined in vivo using dual-energy X-ray absorptiometry (DXA; PIXImus II; GE Lunar, Madison, WI), with lumbar vertebrae (LV1-LV5) and whole leg subregion analyses.
Histological Analysis
Aortic root specimens were embedded in OCT and cryosectioned at 10 lm. Sections were stained for mineralization by the von Kossa silver nitrate method and counterstained with eosin. Immunohistochemical staining was performed using anti-RANKL antibody (R&D Systems, Minneapolis, MN).
Serum Biochemical Assays
Serum RANKL was measured by ELISA (R&D Systems) following the manufacturer's protocol. Serum calcium and phosphate levels were determined using a Hitachi 717 autoanalyzer (Roche Diagnostics, Indianapolis, IN).
Cell Culture
Murine aortic cells (passages 6-10) were isolated from the aortas of C57BL6 [wild-type (WT)] and SM22a-Rankl tg mice as described previously [25] . Cells were maintained in DMEM containing 20 % fetal bovine serum (FBS). One day after plating, cells were treated with forskolin (25 lM) or Pi (3 mM) in aMEM supplemented with 10 % FBS. b-Glycerophosphate (5 mM) was supplemented in control medium and in medium with forskolin.
Matrix Calcium Quantitation
After the indicated periods, matrix calcium levels were analyzed by the o-cresolphthalein complexone method (Teco Diagnostics, Anaheim, CA). Each condition was assayed in quintuplicate and normalized to total protein using the Bradford method [25] .
Alkaline Phosphatase Activity
After the indicated periods, alkaline phosphatase (ALP) activity was assessed colorimetrically using Sigma 104 Phosphatase Substrate (Sigma, St. Louis, MO). Each condition was assayed in quintuplicate and normalized to total protein using the Bradford method [25] .
Gene Expression
Total RNA was isolated from cells using TRIzol reagent (Invitrogen Carlsbad, CA). Real-time RT-qPCR was performed using a one-step method (Biochain Institute, Hayward, CA) in the Mx3005P (Stratagene, La Jolla, CA). b-Actin was used for normalization.
Data Analysis
Each experiment was performed in at least quadruplicate wells and repeated at least three times. Data are expressed as mean ± SEM. Student's t test was used for comparison between two groups. For more than two groups, mean values were compared using one-way ANOVA, with comparison of different groups by Fisher's protected least significant difference test. p B 0.05 was considered significant.
Results
SM22a-Rankl tg Mice
To test the effects of RANKL on vascular calcification specifically, we created RANKL transgenic mice under the control of the SM22a promoter (SM22a -Rankl tg ). Li et al. [24] showed that SM22a expression in vivo is highly restricted to vascular SMCs in adult tissues, and Lepore et al. [26] showed that expression via this promoter is in arterial SMCs as well as in cardiac, but not in skeletal, myocytes. Western blot analysis showed a band with the expected molecular weight of 35 kDa only in the aortic lysates from SM22a-Rankl tg mice (lower band, Fig. 1a) . Consistent with the findings of Lepore et al. [26] , transgene expression was observed in SMCs and cardiomyocytes (Fig. 1a) . There were no obvious phenotypes in the founders, and in male and female mice of the F 1 generation no vascular calcification was detected by DXA analysis (data not shown). Histological analyses by von Kossa staining of aortic sections from 16-month-old SM22a-Rankl tg mice also showed no calcium deposits (Fig. 1b) .
To test whether vascular cell-specific overexpression of RANKL affected circulating levels, serum levels of RANKL were assessed. Results showed that serum RANKL levels were not increased in SM22a-Rankl tg compared with WT mice (Fig. 1c) . As observed in humans, female mice had higher serum RANKL levels than male mice [27] . In male SM22a-Rankl tg mice, serum RANKL was found to be lower than in WT littermates (Fig. 1c) .
We also assessed the effects of vascular cell-specific RANKL expression on body weight, percent fat, and BMD of long bones and vertebrae. Although no weight difference was detected in female mice, male SM22a-Rankl tg mice weighed more than WT mice at 16 months of age (Fig. 2a) . Body fat of the leg was not changed in either male or female mice (Fig. 2b) . In female mice, serum calcium and phosphorus levels and BMD were not altered compared with WT mice (Figs. 2c, 3) . In male SM22a-Rankl tg mice, although serum RANKL levels were lower, serum calcium levels were higher than in WT mice (Fig. 2c) . BMD of lumbar vertebrae, but not of long bones or tibial metaphyses, was less in male SM22a-Rankl tg than in WT mice (Fig. 3 ).
SM22a-Rankl tg SMCs
We further evaluated the osteogenic activity of aortic SMCs from SM22a-Rankl tg mice. The results showed that aortic SMCs from SM22a-Rankl tg mice had substantially higher baseline ALP activity than WT cells at 2 and 4 days of culture (1.2 ± 0.04 vs. 0.09 ± 0.02, p \ 0.001 on day 2; 2.02 ± 0.05 vs. 0.16 ± 0.03, p \ 0.001 on day 4; Fig. 4a ). When induced using the PKA agonist forskolin, ALP activity was induced in both SM22a-Rankl tg and WT SMCs, to a higher level in SM22a-Rankl tg than in WT SMCs (14 ± 4-103 ± 9 vs. 2 ± 0.3-46 ± 2, p \ 0.05; Fig 4b) . Real-time RT-qPCR revealed that baseline expression levels of ALP and ankylosis genes were approximately fivefold and twofold greater in SM22a-Rankl tg compared with WT SMCs, respectively, whereas that of OPG was lower (0.4-fold) (Fig. 4c) . Expression levels of Enpp1, SM22a, and Pit-1 were not significantly different between the groups (data not shown).
When induced by Pi or forskolin, matrix calcium levels were greater in SM22a-Rankl tg than in WT SMCs (Fig. 5a ). Treatment with an ALP inhibitor, levamisole, abolished forskolin-induced, but not Pi-induced, matrix mineralization (Fig. 5b, c) .
Discussion
The RANKL/RANK/OPG axis regulates differentiation of resorptive osteoclasts in bone. RANKL has been implicated in vascular calcification in some studies [19, 20, 28] but not others [21, 22, 29] . These differences may relate to different model systems and cell types. Previous efforts to elucidate its role in vascular calcification in vivo used a transgenic mouse model overexpressing soluble RANKL released from the liver [23] . However, this model was confounded by RANKL induction of skeletal resorption, which may lead to levels of serum phosphate capable of inducing spontaneous soft tissue calcification. To overcome this confounding effect, in the present study we generated transgenic mice with vascular-specific expression of RANKL driven by the SM22a promoter. As evidence that this model provided adequate specificity, there was no significant difference in serum RANKL levels, suggesting that vascular cell-specific overexpression of membrane-bound RANKL overcame the confounding effect. We found that these SM22a-Rankl tg mice did not develop spontaneous vascular calcification.
In cell culture SM22a-Rankl tg SMCs showed significantly greater baseline ALP gene expression and activity than WT SMCs. However, this increase was not sufficient to cause matrix calcification. Possible explanations include that the levels of ALP activity may have been below the threshold required for calcification and/or that the increase in ALP activity may have been overcome by an even greater increase in pyrophosphate, an inhibitor of mineralization which is 1,000-fold more potent an inhibitor than Pi is an activator. The latter possibility is supported by our finding of a simultaneous increase in expression of Ank, the membrane-bound channel responsible for pyrophosphate transport, which may compensate for the increase in ALP. SM22a-Rankl tg SMCs did produce more matrix mineral in response to the procalcific factors Pi and forskolin, and these findings probably have distinct mechanisms. The response to Pi is considered independent of ALP activity, whereas the response to forskolin is considered dependent on ALP activity. The mechanism for reduced expression of OPG is not clear. However, given that Opg -/-mice develop substantial vascular Since in our previous studies, exogenous (soluble) RANKL showed no induction of mineralization in cultured SMCs, there may be a different mechanism for the action of endogenously expressed RANKL in SM22a-Rankl tg SMCs. Another possible explanation for the different effects of exogenous versus transgenic RANKL is that intracellular RANKL may have a novel function in osteoblastic differentiation. Such a phenomenon was reported for intracellular Enpp1, which when altered by overexpression or shRNA, regulated osteoblastic differentiation of a calvarial osteoblastic cell line, in a manner independent of its catalytic activity [30] .
Interestingly, we found effects on serum RANKL levels, body weight, and bone density of lumbar vertebrae that appeared to be gender-specific. The gender differences may be due to effects of estrogen, which has been shown to inhibit RANKL signaling [28] . Gender differences in serum RANKL in our mice are also consistent with the gender differences reported in human studies, with levels almost twice as high in women as in men [27, 31] . Serum RANKL levels are also influenced by female hormonal cycling, with levels higher in the follicular vs. luteal phase [32] . Estrogen is also known to regulate RANKL expression in osteoblasts [33] and in peripheral blood mononuclear cells in humans [34] . The increased body weight observed in male mice does not appear to be due to skeletal effects since BMD was decreased rather than increased. It also does not appear to be due to circulating RANKL levels since the levels were reduced. However, body fat showed a Fig. 2 Physical and biochemical properties of SM22a-Rankl tg mice. Body weight (a), percent body fat of the whole leg (b), and serum calcium and phosphate levels (c) in 16-month-old mice (n = 6/ group). *p = 0.05, **p \ 0.01 Fig. 3 Bone mineral density of SM22a-Rankl tg mice. Dual-energy X-ray absorptiometric analysis of 12-month-old mice (n = 6/group). Lumbar vertebrae (a), tibial metaphyses (b), and whole leg (c). *p \ 0.05 nonsignificant trend toward an increase, which suggests a role of RANKL interactions with neuroendocrine activation [35] .
Although SM22a-Rankl tg mice do not develop spontaneous vascular calcification, it is possible that these mice develop greater vascular calcification than WT mice when exposed to procalcific interventions, such as uremia, renal insufficiency, and/or hyperlipidemia, especially in light of our in vitro finding that transgenic SMCs produce more calcium mineral than WT SMCs in the presence of procalcific factors. 
